BD’s PureWick Trial Shows 70% User Satisfaction; Robotic Pharmacy Market to Reach $396.21M by 2032
BD’s PureWick Female External Catheter improved sleep and comfort for 70% of 165 women in a four-week trial, showing low skin irritation and strong home-usability. The robotic pharmacy prescription market is set to expand from USD 237.65 million in 2026 to USD 396.21 million by 2032 at a 9.18% CAGR.
1. Clinical Trial Demonstrates PureWick Benefits
In a four-week randomized trial involving 165 women, BD’s PureWick Female External Catheter delivered improved sleep quality and overall comfort compared with traditional urinary pouches. Participants reported low incidence of skin irritation, ease of placement and removal, and approximately 70% indicated they would continue use in a home setting, underscoring potential adoption among older adults.
2. Robotic Pharmacy Prescription Market Outlook
The global robotic pharmacy prescription market grew from USD 214.16 million in 2025 to USD 237.65 million in 2026 and is forecast to reach USD 396.21 million by 2032 at a 9.18% CAGR. Growth is driven by automation for medication safety, a shift of pharmacists to clinical roles, and bundled solution strategies across hospitals, clinics and long-term care facilities.